In a pilot ProtoArray analysis, we identified 6 proteins out of 9483 recognized by autoantibodies (AAb) from patients with systemic sclerosis (SSc). We further investigated the 6 candidates by ELISA on hundreds of controls and patients, including patients with Systemic Lupus Erythematosus (SLE), known for high sera reactivity and overlapping AAb with SSc. Only 2 of the 6 candidates, Ephrin type-B receptor 2 (EphB2) and Three prime Histone mRNA EXonuclease 1 (THEX1), remained significantly recognized by sera samples from SSc compared to controls (healthy or with rheumatic diseases) with, respectively, 34% versus 14% (P = 2.10 −4
Introduction
Systemic sclerosis (SSc) is a rare severe chronic autoimmune disease beginning with vascular damage, causing collagen synthesis dysfunction and fibrotic phenotype in the skin and internal organs [1] . It is different from localized scleroderma (LocSc) or morphea which classically presents benign and self-limited evolution and is confined to the skin and/or underlying tissues. Systemic sclerosis remains difficult to diagnose because of clinical heterogeneity. Two main forms of SSc have been defined: limited cutaneous disease (lcSSc) characterized by skin involvement below the elbows and knees and diffuse cutaneous disease (dcSSc) for which skin involvement is more extended. More than 80% of patients with SSc have anti-nuclear antibodies (ANA). Some specific autoantibodies correlate with clinical subtypes and are helpful for diagnosis and clinical classification: anti-centromere antibodies (ACA or anti-CENP-B) and antitopoisomerase antibodies (ATA or anti-Scl-70) are respectively markers of lcSSc and dcSSc present in 65% and 40% of patients in each clinical subgroup [2] . Additionally the new Classification Criteria for SSc includes the anti-RNA polymerase III antibodies [3] , associated with the diffuse cutaneous form of SSc and renal crisis [4, 5] , although only present in 6-9% of French patients with SSc [6] . Other biomarkers can be used for SSc classification, although less frequent and less frequently used in routine: anti-fibrilllin (AFA), anti-Th/To, anti-Pm/Scl or anti-U3RNP are associated with particular clinical manifestations [7] [8] [9] [10] .
Nevertheless about one third of patients with SSc have none of the above mentioned SScspecific autoantibodies in their sera and a need for new biomarkers is obvious in a disease still difficult to be diagnosed or classified.
Similarly, patients with Systemic Lupus Erythematosus (SLE) have IgG autoantibodies against more than a hundred different antigens including DNA, nucleosomes, histones, viral antigens, transcription factors, only few are useful for the diagnosis of SLE [8] . Patients with SLE are known for high sera reactivity and for having overlapping AAb with SSc.
Anti-dsDNA antibodies help to monitor disease activity and anti-Smith (anti-Sm) antibodies are highly specific for SLE diagnosis [9] . Still, 20 to 30% of patients with SLE do not have anti-dsDNA antibodies and 60 to 80% do not have anti-Sm antibodies. A specific marker for SLE and particularly for disease activity would therefore be useful to adjust treatments.
To identify new autoantibodies in SSc, we first screened 9483 human proteins spotted on protein arrays with 20 sera from patients with SSc, including patients positive for ACA (ACA pos ), positive for ATA (ATA pos ) or negative for both antibodies (ATA/ACA neg ) and 18 sera from controls (healthy and with other autoimmune diseases (AID)). Six proteins were recognized by autoantibodies from half of the patients with SSc and none of the controls: Fibroblast Growth Factor 2 (FGF2), Allograft Inflammatory Factor 1 (AIF1), Ephrin Type-B receptor 2 (EphB2), Dual specificity protein kinase CLK1, Three prime Histone mRNA EXonuclease 1 (THEX1) and Ankyrin repeat and Sterile alpha motif domain containing 6 (ANKS6). The same six human proteins as those spotted on protein arrays were separately purchased and coated in 96 well plates to be tested by ELISA and further challenged on a large number of patients and controls.
By ELISA, only Ephrin type-B receptor 2 (EphB2) and Three prime Histone mRNA EXonuclease 1 (THEX1) remained significantly recognized by autoantibodies from patients with SSc and were further tested to reach a total of respectively 336 and 362 individuals including patients with SSc, with Systemic Lupus Erythematosus (SLE) Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and healthy controls (HC).
Patients and Methods

Criteria for patients and controls
Patients with Systemic scleroderma (SSc) fulfilled the criteria of LeRoy for SSc [11] , while patients with localized scleroderma (LocSc or morphea) were distinguished according to the international classification [12] . Patients with RA satisfied the 2010 revised criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) [13] . Patients with SLE fulfilled the American College of Rheumatology revised criteria for SLE [14] as updated in 1997 [15] . Patients with Psoriatic Arthritis (PsA) fulfilled the ClASsification of Psoriatic ARthritis (CASPAR) criteria [16, 17] and patients with Ankylosing Spondylitis (AS) fulfilled the Assessment of SpondyloArthritis international Society classification criteria [18] .
Healthy controls had no history of autoimmunity and were recruited at the 
Ethics statements
All participants signed informed consent according to the Declaration of Helsinki [19] . The study is registered at the INSERM under the Biomedical Research Protocol number RBM-04-10 and received the approval of the "Comité de Protection des Personnes de Marseille II" or as a collection registered under the number DC-2008-327.
Participants' characteristics for ProtoArray analysis
For ProtoArray analysis, sera samples from 20 patients with SSc, including 8 patients negative for ACA and ATA (ACA/ATA neg ), 6 positive for ATA and 6 positive for ACA, were compared to 18 controls. Controls included 8 healthy individuals with no history of autoimmune diseases (AID) and 10 patients with other AID including 7 Rheumatoid Arthritis (RA), 1 Systemic Erythematous Lupus (SLE) and 2 Localized Scleroderma (LocSc), the latter being tested to distinguish their profile from systemic sclerosis. 
Epitope mapping on EphB2 and THEX1 protein
In order to determine which part of the protein was recognized by autoantibodies, we performed an epitope mapping for EphB2 and THEX1. A total of thirty-four 15-mer peptides encompassing residues from EphB2 (locus NM_004442.3) overlapping on 7 or 8 amino acids and sixteen 20-mer peptides encompassing residues from THEX1 (locus NM_153332.2) overlapping on 10 amino acids were synthesized using the solid-phase system, and then purified (Polypeptide Laboratories, Strasbourg, France). Plates were coated overnight with 10 μg/well peptides diluted in PBS, pH 7.4 as previously described [20] . Plates were blocked washed and revealed similarly to the ELISA plates presented above. Sera, diluted to 1:100 in PBS 1% BSA, were incubated for 2 h. Positive wells were defined as above (ΔAbs = 0 or more).
Statistical analysis
To determine whether a candidate protein was significantly better recognized by autoantibodies from patients with SSc or patients with SLE rather than healthy controls and/or patients with other rheumatic diseases, p values were calculated using the χ 2 test and corrected for multiple comparisons (Bonferroni) depending on the number of groups tested (i.e. when 3 groups were compared-SSc, HC and other rheumatic diseases (RD)-a correction by 3 was applied). For ΔAbs comparisons between groups, p values were evaluated using Mann Whitney test. Correlation between ΔAbs and severity of the disease (SLEDAI) for SLE was assessed by Spearman's rank test (Graphpad Prism 6).
To evaluate diagnostic ability of each tested protein for SSc and SLE, plots of sensitivity versus 1-Specifity or Receiver Operating Characteristic (ROC) curves have been realized and the area under the curve (AUC) is given for each protein and disease (Graphpad Prism 6).
Results
Identifying new autoantibodies for SSc diagnosis by ProtoArray
analysis
By Protoarrays, we aimed at identifying circulating antibodies that react with specific proteins and were associated with SSc. To validate highly specific and new candidates for SSc diagnosis with an unbiased method, we arbitrarily selected human proteins, among the 9483 present on the chips, which were recognized by sera from at least 50% of the 20 patients with SSc tested and never recognized by sera of the 18 controls (including patients with AID and healthy controls). Only six protein candidates (Table 1) Anti-EphB2 and anti-THEX1 autoantibodies in Scleroderma and Lupus
The six proteins were separately purchased and tested on a larger number of sera from patients and controls for the presence of AAb. To set-up ELISA working conditions, we first tested patients who had been positive for anti-FGF2, -AIF1, -EphB2, -CLK1, -THEX1 or -ANKS6 AAb by Protoarrays and defined most of them being positive by ELISA at sera dilution 1:100 and at protein concentration of 0.2μg/well, except ANKS6 for which 0.1μg/well was sufficient to detect positive samples. Only EphB2 and THEX1 remained significantly recognized by respectively 34% and 60% of sera samples from patients with SSc compared to 14% and 28% (P = 2.10 −4 , P = 3.10
) of sera samples from all controls including sera samples from healthy controls and from patients with other rheumatic diseases (Fig 1) . THEX1 proteins. Under our ELISA conditions, both proteins are significantly recognized by sera from patients with systemic sclerosis (SSc) and patients with Systemic Lupus Erythematosus (SLE), when compared to both sera from healthy controls (HC) and sera from patients with other rheumatic diseases (RD). All p values (P) are calculated after Bonferroni correction. P 1 : patients with SSc or SLE compared to HC, P 2 : compared to RD, P 3 : compared to both HC and RD.
Patients with SLE, known for high sera reactivity and overlapping AAb with SSc, were tested in parallel for both proteins and showed a higher reactivity against EphB2 and THEX1 than SSc sera. EphB2 and THEX1 were recognized by respectively 56% and 82% of sera samples from patients with SLE compared to 14% and 28% of other controls (P = 2.10 −10 and P = 5.10 −13 ).
Clinical and serological characteristics of patients with SSc having antiEphB2 or anti-THEX1 autoantibodies
We observe in our study that men with SSc had a tendency to have more often anti-EphB2 AAbs than women with SSc, although without reaching significance ( Table 2 , P = 0.053). Otherwise patients with SSc were not significantly different in age at diagnosis, had similar disease duration and did not differ in ethnicity or clinical subtypes (diffuse or limited SSc), whether they were positive or negative for anti-EphB2 or anti-THEX1 AAb. Patients had similar organ involvement at the time of their blood draw whether they were positive or negative for both AAb except for patients negative for EphB2 AAb for whom joint involvement was marginally more frequent (P = 0.04). Treatments were similar in any groups (data not shown). Nevertheless, when patients were classified according to classical SSc-specific AAb status (ATA pos , ACA pos or ATA/ACA neg ), those without classical SSc-AAb (ACA/ATA neg ) were the one who had more often anti-EphB2 AAb (44%) and with the highest Absorbance levels (P<0.0001, Fig 2A) . On the other hand, anti-THEX1 AAb could similarly diagnose any patients with SSc, whether they had or not classical SSc-AAb (Fig 2B) . Other AAb, antids-DNA, -SSA, -SSB, -RNP, -PmScl or anti-Jo1 antibodies did not reveal any particular pattern in one group or the other and were rare enough to allow statistical evaluations (data not shown).
Clinical and serological characteristics of patients with SLE having antiEphB2 or anti-THEX1 autoantibodies
Patients with SLE were not significantly different in gender, ethnicity, whether they were positive or negative for anti-EphB2 or anti-THEX1 AAb (Table 3) . Patients with anti-EphB2 AAb had more often experienced cardiovascular events than patients negative for this AAb (P = 0.015, two-sided Fisher's exact test), whereas patients with anti-THEX1 AAb had more often an active disease (without reaching significance), were more often positive for anti-dsDNA AAb (P = 0.017) and had more often joint involvement (P = 0.019). Anti-EphB2 AAb could diagnose any patient with SLE whether they had or not typical SLE autoantibodies, anti-dsDNA (dsDNA pos or dsDNA neg , Fig 3A) . Anti-THEX1 AAb preferentially diagnosed SLE patients with anti-dsDNA AAb.
Treatments were similar in any groups (EphB2 pos or EphB2 neg and THEX1 pos or THEX1 neg ); they were often under corticoids or hydroxychloroquine (data not shown).
Nevertheless in anti-THEX1 AAb detection assays, absorbance levels were higher for patients with SLE (Mean ΔAbs: 0.129, Fig 3B) than for patients with SSc (Mean ΔAbs: 0.01, Fig  2B) , suggesting higher AAb titers in the former. Moreover, not only did anti-THEX1 AAb preferentially diagnosed SLE patients with anti-dsDNA AAb, a marker of disease activity, but highest absorbance levels significantly correlated with higher disease activity indexes (Fig 4) . 
Comparison of anti-THEX1 and anti-EphB2 AAb for their ability to diagnose SSc and SLE
To evaluate diagnostic ability of each tested protein for SSc and SLE, plots of sensitivity versus 1-Specifity or Receiver Operating Characteristic (ROC) curves have been realized by comparing results in each disease to all other subjects. The presence of anti-THEX1 AAb or antiEphB2 AAb is a good diagnostic tool for SLE even when patients with SSc are also considered as controls with healthy controls and controls with RD (areas under the curve (AUC) of 0.80 and 0.74 respectively). On the opposite, and expected from results above, EphB2 and THEX1 are not diagnostic tools for SSc when among controls patients with SLE are also included (Fig 5) .
Anti-THEX1 AAb detection assay allowed a sensitivity of 82% and a specificity of 59% for SLE diagnosis. Anti-EphB2 AAb detection assay allowed a sensitivity of 56% and a specificity of 79% for SLE.
Combination of both proteins (having both anti-THEX1 and anti-EphB2 AAb) allowed to identify 49% (17/35) of patients with SLE, 26% (26/100) of patients with SSc and only 3% (5/ 153) of all other controls. This gives for SLE diagnosis a lower sensitivity (49%) but a better Organ involvement (%) (n = 31) (n = 21) (n = 41) (n = 8) Anti-EphB2 and Anti-THEX1 Autoantibodies in Scleroderma and Lupus Anti-EphB2 and Anti-THEX1 Autoantibodies in Scleroderma and Lupus specificity (88%) than evaluation of individual proteins. For SSc, this allows 26% of sensitivity and 88% of specificity.
Epitope mapping on EphB2 and THEX1 protein
Although anti-EphB2 and anti-THEX1 autoantibodies were better tools for SLE diagnosis, they were nevertheless found in SSc. We therefore proposed to define disease specific autoantigenic epitopes on both proteins to better refine SSc and SLE diagnosis by screening peptides encompassing residues from EphB2 and THEX1.
Out of the thirty-four 15-mer EphB2 peptides screened, we could find one peptide specifically recognized by sera from patients with SLE: the peptide #7, P7 (Phe-Leu-Ser-Glu-Ala-SerIle-Met-Gly-Gln-Phe-Asp-His-Pro-Asn-NH2). P7 was recognized by 35.4% of patients with SLE (n = 48, P<10 ) compared to 5% of all other individuals (N = 157), including 5.4% of patients with SSc (n = 56), 6.5% of patients with RA (n = 46) and 3.6% of healthy controls (n = 55). Sera samples from patients with SLE had titers significantly higher than any other sera (P<0.0001, Fig 6) . Roc curve for P7 showed an AUC of 0.73. Anti-P7 AAb detection assay allowed a sensitivity of 35% and a specificity of 95% for SLE diagnosis (Fig 7) .
Interestingly, 30% of sera from patients with SLE without anti-dsDNA-autoantibodies were positive for anti-P7 AAb (data not shown). Notwithstanding, higher anti-P7 antibody absorbances correlated with higher disease indexes and could be a marker of disease activity, although the correlation was marginally significant (Spearman's rank test, p<0.02, Fig 8) . Anti-EphB2 and Anti-THEX1 Autoantibodies in Scleroderma and Lupus
We could not find an epitope on EphB2 protein specifically recognized by sera from patients with SSc.
THEX1 epitope mapping was similarly realized but we could not find an epitope for SSc or SLE (16 peptides tested, data not shown).
Discussion
Using ProtoArray 1 method, we first defined 6 out of 9483 spotted human proteins specifically recognized by IgG autoantibodies from 20 sera of patients with SSc: Fibroblast Growth Factor 2 (FGF2), Allograft Inflammatory Factor 1 transcript variant 1 (AIF1), Ephrin Type-B receptor 2 (EphB2), Dual specificity protein kinase CLK1 (CLK1), Three prime Histone mRNA EXonuclease 1 (THEX1) and Ankyrin repeat and Sterile alpha motif domain containing 6 (ANKS6). Autoantibodies against these proteins have never been described before in SSc, although some of the proteins are involved in SSc pathogenesis. High levels of FGF2, a pro-angiogenic growth factor, are present in plasma from patients with SSc and participate in angiogenesis deregulation in SSc [21] . Overexpression of AIF1, a cytoplasmic inflammation-responsive protein, is observed in affected blood vessels of the lung and skin from patients with SSc, in particular in untreated patients, with early onset of disease [22] . Moreover, several single nucleotide Anti-EphB2 and Anti-THEX1 Autoantibodies in Scleroderma and Lupus polymorphisms (SNPs) have been described in AIF1 gene and some are associated with SSc [23, 24] . Finally, one of the 3 ligands of EphB2, Ephrin B2, a protein involved in angiogenesis, is up-regulated in clinically involved skin of SSc patients [25] . Therefore, finding autoantibodies against these proteins has a particular signification in the context of scleroderma. Nevertheless, our protoarray study was driven on a limited number of sera, because of the expensive price of chips, and selected proteins needed to be confirmed for their antigenicity by ELISA on larger number of patients and controls. When tested on more than one hundred sera from patients with SSc, only anti-EphB2 and anti-THEX1 autoantibodies remained statistically more often present in SSc sera compared to other sera from healthy controls or other rheumatic diseases (RA, PsA and AS) in our ELISA conditions. THEX1, also called ERI-1, is a 3'-5' exoribonuclease: it binds to the 3' end of histone mRNAs and degrades them by removing terminal nucleotides from the 3' end [26] . It may play an essential role in histone mRNA decay after replication. It is also able to bind other mRNAs and degrade the 3'-overhangs of short interfering RNAs (siRNAs) and microRNAs [27] .
According to our results, THEX1 could be a good diagnostic marker for SSc patients whether they have or not classical SSc autoantibodies (ATA or ACA) as 60% of patients with SSc had AAb in their sera compared to only 28% of healthy controls or controls with RD. Nevertheless when THEX1 was tested for its reactivity on sera samples from patients with SLE, known for having AAb against several proteins including some shared with SSc, THEX1 was a better diagnosis tool for lupus, with 82% of sera recognizing the protein. It could also be a good predictor of flares in SLE as higher anti-THEX1 AAb titers correlated with higher disease activity indexes (P = 0.0002). Still, AAb against THEX1 were present in sera from both diseases, we therefore proposed to define disease specific autoantigenic epitopes to better refine SSc and SLE diagnosis by screening peptides encompassing residues from THEX1. Unfortunately, we could not identify a particular epitope for SSc or for SLE on THEX1 protein. This could be due to conformational epitopes that would not be recognized when using linear peptides.
As indicated by its RNA-specific functions THEX1 localizes mostly in the cytoplasm. This suggests that autoantibodies recognizing THEX1, in SSc or SLE, may appear after cell death and exposure of intra-cytoplasmic proteins, or could, as seen for other auto-antibodies [28, 29] , penetrate into living cells and migrate to the cytoplasm to bind to cytoplasmic THEX1 proteins. We do not know, and this is beyond the scope of the current study, whether autoantibodies against THEX1 impair its exonuclease function.
Eph receptor tyrosine kinases and their Ephrin ligands represent an important signaling system with widespread roles in cell physiology and disease [30] . Receptors and ligands in this family are anchored to the cell surface and the B family of Eph receptors and Ephrin ligands play essential roles in vascular development and postnatal angiogenesis [30] . EphB receptors and ephrin B ligands are expressed by endothelial cells from various tissues.
EphB2 is a good diagnostic marker for SSc as it is recognized by AAb from 34% of patients compared to only 14% of controls. Moreover 44% of patients who do not have classical SScspecific autoantibodies (ATA/ACA neg ) had anti-EphB2 AAb. Nevertheless EphB2 revealed to be better diagnostic tool for SLE as 56% of SLE sera were positive for anti-EphB2 AAb. Moreover, we could spot a 15-mer peptide (P7) on EphB2 protein allowing a 95% specificity for SLE diagnosis with a 35% sensitivity. Anti-P7 antibody titers correlated with disease indexes (SLE-DAI) and could be a marker of disease activity. In our conditions, we could not find a SSc-specific epitope on EphB2 protein. Anti-EphB2 and Anti-THEX1 Autoantibodies in Scleroderma and Lupus Anti-EphB2 AAb may have a role on vascular functions in both diseases. Furthermore both SLE and SSc are characterized by vascular inflammation, altered angiogenesis, and increased cardiovascular morbidity and mortality. We did not find any difference for cardiovascular involvement at the time of blood draw between patients with SSc positive or negative for antiEphB2 AAb. This is perhaps due to the fact that all the vascular changes occur in almost all of SSc patients very early in the disease with variable degrees of severity latter. Indeed we had a 10 year follow-up for 11 patients and results indicate that one third of patients have now vascular involvement among patients who were positive for EphB2 AAb and none among patients negative for EphB2 AAb (data not shown). Moreover, we found that men with SSc have a tendency to have more often anti-EphB2 AAbs than women with SSc (p = 0.053). This is an interesting observation, knowing that, although more common in women, SSc appears as strikingly more severe in men and recent results obtained through the EULAR Scleroderma Trials and Research group database demonstrate a higher risk of severe cardiovascular involvement in men [31] .
Vasculopathy is also one of the typical symptoms reported in SLE but only in 10 to 40% of patients and may precede the development of a full-blown SLE [32] . Interestingly, we observed that patients with lupus positive for anti-EphB2 AAb had more often experienced cardiovascular events than patients negative for this AAb at the time of blood draw.
Anti-EphB2 autoantibodies are not only good tools for SLE diagnosis, but may have a functional role in vasculopathy. It is to note that AAb recognize the kinase domain of EphB2, an intracytoplasmic region. Again AAb may recognize intracytoplasmic exposed protein structures after cell death or may penetrate living cells and interfere with protein function. This is also behind the scope of this study but future studies would be worth exploring whether antiEphB2 AAb are capable to penetrate living endothelial cells and dysregulate endothelial cell sprouting. Recent work has reported that EphB2 participate in complex molecular mechanisms that drive endothelial cell movement and the formation of new vessels [33] . If indeed antiEphB2 AAb disturb the vascular network, this gives also therapeutic perspectives to the peptide P7, or peptides encompassing this epitope, as a tolerogenic peptide hampering AAb to react against their target.
Conclusion
In conclusion, we showed that patients with SSc or SLE have AAb against EphB2, a protein involved in angiogenesis, and THEX1, a 3'-5' exoribonuclease involved in histone mRNA degradation. Both proteins are interesting for SSc diagnosis particularly for being recognized by sera from patients without classical SSc autoantibodies (anti-centromere and anti-topoisomerase antibodies). Nevertheless anti-EphB2 and anti-THEX1 AAb are more often and at higher titers present in sera from SLE patients. Moreover, we have further identified a 15-mer peptide from EphB2 protein as a specific and sensitive tool for SLE diagnosis.
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